WAY-600 is a selective single digit nanomolar ATP-competitive mTOR inhibitor with an IC50 of about 9 nM. It has significant selectivity for these enzymes over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold). With the 11% suppression by rapamycin, WAY-600 treated HEK293 cells indicated a 50% inhibition of polysomes. And WAY-600 blocked mTORC2-dependent phosphorylation of AKT in vitro and in vivo acutely. Without significant inhibition of P-AKT(T308), WAY-600 inhibited the mTORC1 substrate P-S6K(T389) and mTORC2 substrate P-AKT(S473) at submicromolar concentrations in various cancer cells.
|Source||Biochem Biophys Res Commun (2016). Figure 1.WAY-600|
|Cell Lines||HCC cell|
|Incubation Time||48 h|
|Results||Results in Fig. 1A showed thatWAY-600, at 10e1000 nM, significantly decreased MTT viability OD of HepG2 cells.|
|Cell lines||MDA361 and U87MG cells|
|Preparation method||Cell lines of Rat1, HEK293, MDA-MB-361, MDA-MB-468, MDA-MB-231, LNCap, DU145, U87MG, A498, HCT116, and HT29 were obtained from the American Type Culture Collection. PC3MM2 was obtained from Dr. Carolyn Discafani (Wyeth Discovery Oncology). All cells were cultured using standard cell culture methods. For tumor cell growth assays, cells were plated in 96-well culture plates at 1000 to 3000 cells per well for 24 h, treated with DMSO or various doses of mTOR inhibitors. Viable cell densities were determined three days later by MTS assay employing an assay kit (CellTiter 96® AQueous, Cat # G5421, Promega) following the kit assay protocol. The effect of each treatment was calculated as percent of control growth relative to the DMSO-treated cells grown in the same culture plate. Inhibitor dose response curves were plotted for determination of IC50 values.|
|Incubation time||3 days|
|Animal models||PC3MM2 tumors xenograft model in BALB/c nu/nu female mice|
|Formulation||5% ethanol, 5% polysorbate 80, 5% polyethylene glycol-400|
|Dosages||50mg/kg on days 0 to 4 once daily or twice daily|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO ≥15 mg/mL|
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K, et al. Cancer Res. 2009 Aug 1;69(15):6232-40. PMID: 19584280.
|Related mTOR Products|
CZ415 is a potent ATP-competitive mTOR inhibitor with very good cell permeability.
GNE-477 is a potent and efficacious dual PI3K (IC50=4 nM)/mTOR(Ki=21 nM) inhibitor.
Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.
LY303511 is a structural analogue of LY294002, which does not inhibit PI3K, increased homotypic GJIC.
Temsirolimus (CCI-779) is a specific mTOR inhibitor with IC50 of 1.76 μM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.